[ Search Options ]

Steven E. Hyman, M.D.

Name, Degree: Steven E. Hyman, M.D.
Role(s) in Work Group: Member, Task Force
Institutional Affiliation(s): Harvard University
City, State Cambridge, MA

Biographical Sketch:

Steven E. Hyman, MD is Provost of Harvard University and Professor of Neurobiology at Harvard Medical School. From 1996 to 2001, he served as Director of the National Institute of Mental Health (NIMH), the component of the US National Institutes of Health charged with generating the knowledge needed to understand and treat mental illness. Before serving as Director of NIMH, Dr. Hyman was Professor of Psychiatry at Harvard Medical School, Director of Psychiatry Research at Massachusetts General Hospital, and the first faculty Director of Harvard University's Mind, Brain, and Behavior Initiative. In the laboratory he studied the regulation of gene expression by neurotransmitters, especially dopamine, and drugs that act on dopamine receptors. Dr. Hyman is a member of the Institute of Medicine of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, and a Fellow of the American College of Neuropsychopharmacology. He is Editor of the Annual Review of Neuroscience. He received his BA from Yale College in 1974 summa cum laude, and his MA from the University of Cambridge in 1976, which he attended as a Mellon fellow studying the history and philosophy of science. He earned his MD from Harvard Medical School in 1980 cum laude.

Non-Profit and Advocacy Organizations	Year(s)	Role
Annual Reviews	2003 - 2008	Board
Dana Foundation	2004 - 2008	Board
Biomed Central	2002 -2008	Board
Alzheimer's Study Group	2007 – 2008	Member

The two tables below represent Dr. Hyman’s disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of year.

Dr. Hyman has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed $10,000 in any calendar year.

KEY NUMBER:
1. Consultation Fees (include scientific advisory boards)
2. Full- or Part-time Employee
3. Industry-related Grant-Research Support received or pending
4. Honoraria (includes Speakers’ Bureau)
5. Stock or other financial options

6. Expert testimony
7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)
8. Patents received or pending
9. Officer, director/trustee, executive (specify)
10. Other (specify)

Disclosure of significant interests for 2005, 2006, and 2007

Commercial or Other Organization	Year(s)	Key #(s)
Neurion	2002 – 2007	1
Seaside Therapeutics	2006 - 2007	1
Fidelity Biosciences	2007	No relation to Psychiatry
Merck	2002-2006	1
Glaxo Smith Kline	2007	1